N4 Pharma PLC - pharmaceutical company - Appoints the API and Nanomedicines business unit of Ardena as its contract development & manufacturing organisation partner for the technology transfer and upscaling manufacture of Nuvec. Ardena is based in the Netherlands with substance and drug product manufacturing capability and is experienced in the manufacture of nanoparticles. "As we look to continue the advancement of Nuvec and its applications it is increasingly important that we have access to a consistent Nuvec product across our studies together with the potential to move to GMP certification as and when required and Ardena can provide this," said N4 Chief Executive Nigel Theobald.
Current stock price: 12.00 pence
Year-to-date change: more than quadrupled
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
N4 Pharma Plc (N4P)